PET-CT在调强适形放疗中的临床应用

司宏伟; 耿建华; 陈盛祖

PET-CT在调强适形放疗中的临床应用

司宏伟 , 耿建华 , 陈盛祖

文章导航 > 国际放射医学核医学杂志 > 2005, 29 > 5: (223-226)

引用本文:

Citation:

PET-CT在调强适形放疗中的临床应用

100021 北京, 中国医学科学院中国协和医科大学肿瘤医院核医学科
中图分类号: R814.42;R817.4

Clinical application of PET-CT in intensive modulated radiotherapy

Department of Nuclear Medicine, Cancer Hospital, Chinese Academy of Medical Science, Peking Union Medical College, 100021 Beijing, China
CLC number: R814.42;R817.4

摘要: PET技术的快速发展使其在肿瘤分期和放疗计划(RTP)的制定中拥有了更大的应用空间。PET可以得到更多的肿瘤生物学信息(如肿瘤细胞密度、对射线敏感情况等信息),该生物学信息与CT或MRI的解剖学信息一起,为在放疗中锁定肿瘤细胞提供新的思路。以PET-CT为基础的调强适形放疗(IMRT),充分利用融合技术显示解剖生理靶区的能力,并在放疗计划中引入了生物靶区的概念。从理论上说,以PET-CT为基础的IMRT能在¹⁸F-氟代脱氧葡萄糖(¹⁸F-FDG)高代谢区提高最大日照射剂量,从而取得更好的疗效。因此,PET-CT的肿瘤诊断技术和IMRT共同开拓了最佳生物放疗新领域。
- 三维适形放疗 /
- 正电子发射体层显像 /
- 计算机体层成像 /
- 调强适形放疗 /
- 放疗计划
Abstract: The technology of PET had developed rapidly, and made it more and more important in stage and radiotherapy of tumor. The results of PET can give some biological information, such as the density of tumor and the sensitiveness to radiotherapy, these information together with the morphologic modalities, for example CT and MRI, offer a new opportunity to target the tumor cell in the therapy. Intensive Modulated Radiotherapy based on PET-CT, have the ability to display the biologic target through the fusion image of PET and CT, and create the concept of biologic target volume. In theory, within the high metabolic region of fluorideoxyglucose, you can apply a higher appropriate daily radiotherapy dose for better result. So the tumor diagnostic technology of PET-CT and IMRT bring a new biologic radiotherapy into reality.
- three-dimensional conformal radiotherapy /
- positron emission tomography /
- computed tomography /
- intensive modulated radiotherapy /
- radiotherapy planning
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Ahamad A, Jhingran A. New radiation techniques in gynecological cancer[J]. Int Gynecol Cancer, 2004, 14(3):569-579.
[2]	Vogel WV, Oyen WJ, BarentszJO, et al. PET-CT:panacea,redundary, or something in between?[J]. J Nucl Med, 2004, 45(1S):15-24.
[3]	Bradley JD, Perez CA, Dehdashti F, et al. Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer[J]. J Nucl Med, 2004, 45(1S):96-101.
[4]	Brahme A. Recent advances in light ion radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2004, 58(2):603-616.
[5]	Brahme A. Biologically optimized 3-dimensional in vivo predictive assay-based radiation therapy using positron emission tomographcomputerized tomography imaging[J]. Acta Oncol, 2003, 42(2):123-136.
[6]	Girand P, Grahed D, Montravers F, et al. CT and (18)F-deoxyglucose (FDG)image fusion for optimization of conformal radiotherapy of lung cancer[J]. Int J Radiat Oncol Biol Phys, 2001, 49(5):1249-1257.
[7]	Bradley JD, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2004, 59(1):78-86.
[8]	Mah K, Caldwell C, Ung Y, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small cell lung carcinoma:a prospective study[J]. Int J Radiat Oncol Biol Phys, 2002, 52(2):339-350.
[9]	Scarfone C, Lavely WC, Cmelak AJ, et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaing[J]. J Nucl Med, 2004, 45(4):543-552.
[10]	Ciernik IF, Dizendor E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography(PET-CT):a feasibility study[J]. Int J Radiat Oncol Biol Phys, 2003, 57(3):853-863.
[11]	Czernin J, Phelps ME. Positron emission tomography scanning current and future applications[J]. Annual Rev Med, 2002, 53(2):89-112.
[12]	Weder W, Schmid RA, Bruchhaus H, et al. Detection of extra thoracic metastases by positron emission tomography in lung cancer[J]. Ann Thorac Surg, 1998, 66(3):886-892.
[13]	Dizendort E, Baumert BG, Von Schul-Chess GK, et al. Impact of whole body ¹⁸F-FDG PET on staging and managing patients for radiation oncology[J]. J Nucl Med, 2003, 44(1):24-29.
[14]	Leviver M, Massager N, Wikler D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors:clinical experience and proposed classification[J]. J Nucl Med, 2004,45(7):1146-1154.
[15]	Mutic S, Malyapa RS, Grigsby PW, et al. PET guided IMRT for cervical carcinoma with positive para-aortic lymphnodes:A dose-escalation treatment planning study[J]. Int J Radiat Oncol Biol Phys, 2003,55(1):28-35.
[16]	Esthappan J, Mutic S, Malyapa RS, et al. Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive para-aortic lymphnodes[J]. Int J Radiat Oncol Biol Phys, 2004, 58(4):1289-1297.
[17]	MacManus MP, Hicks RJ, Ball DL, et al. F-18-fluorodexyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma:powerful correlation with survival and high impact on treatment[J]. Cancer, 2001, 92(4):886-895.

[1]	吴伟章 . 三维适形放疗和调强放射治疗. 国际放射医学核医学杂志, 2004, 28(4): 185-188.
[2]	吴湖炳 . ¹⁸F-氟代脱氧葡萄糖PET-CT在头颈部肿瘤中的应用价值. 国际放射医学核医学杂志, 2005, 29(5): 205-209.
[3]	王利伟 , 王自正 , 顾建平 , 王丽萍 , 王峰 . 孤立性肺结节的影像学研究进展. 国际放射医学核医学杂志, 2005, 29(6): 248-251.
[4]	季仲友 . PET-CT中诊断性CT的必要性与临床应用. 国际放射医学核医学杂志, 2005, 29(5): 197-200.
[5]	华逢春 , 管一晖 , 赵军 . ¹⁸F-氟代脱氧葡萄糖PET及PET-CT在淋巴瘤中的临床应用. 国际放射医学核医学杂志, 2005, 29(5): 216-219,226.
[6]	董孟杰 , 林祥通 , 赵军 . PET-CT在卵巢癌中的临床应用价值. 国际放射医学核医学杂志, 2005, 29(5): 209-213.
[7]	陈香 , 赵军 , 管一晖 . PET-CT常见伪影. 国际放射医学核医学杂志, 2005, 29(5): 201-205.
[8]	张锦明 , 田嘉禾 . 11C标记的放射性药物在PET-CT肿瘤诊断上的应用. 国际放射医学核医学杂志, 2005, 29(5): 232-237.
[9]	刘建军 , 黄钢 . ¹⁸F-氟代脱氧葡萄糖PET和PET-CT在转移性骨肿瘤中的应用研究. 国际放射医学核医学杂志, 2005, 29(5): 213-216.
[10]	黎海涛 . PET-CT在乳腺癌诊断中的应用价值. 国际放射医学核医学杂志, 2005, 29(5): 220-222.

点击查看大图

计量

文章访问数: 1081
HTML全文浏览量: 104
PDF下载量: 2

PET-CT在调强适形放疗中的临床应用

100021 北京, 中国医学科学院中国协和医科大学肿瘤医院核医学科

收稿日期: 2004-11-14

关键词:

摘要: PET技术的快速发展使其在肿瘤分期和放疗计划(RTP)的制定中拥有了更大的应用空间。PET可以得到更多的肿瘤生物学信息(如肿瘤细胞密度、对射线敏感情况等信息),该生物学信息与CT或MRI的解剖学信息一起,为在放疗中锁定肿瘤细胞提供新的思路。以PET-CT为基础的调强适形放疗(IMRT),充分利用融合技术显示解剖生理靶区的能力,并在放疗计划中引入了生物靶区的概念。从理论上说,以PET-CT为基础的IMRT能在¹⁸F-氟代脱氧葡萄糖(¹⁸F-FDG)高代谢区提高最大日照射剂量,从而取得更好的疗效。因此,PET-CT的肿瘤诊断技术和IMRT共同开拓了最佳生物放疗新领域。